AI assistant
MetaVia Inc. — Director's Dealing 2022
Jul 28, 2022
34919_dirs_2022-07-28_f69cbde3-f16b-4a3d-8ab7-c619bb4b3f17.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NeuroBo Pharmaceuticals, Inc. (NRBO)
CIK: 0001638287
Period of Report: 2022-07-26
Reporting Person: Kim Na Yeon (Director, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-07-26 | Common Stock | J | 1445267 | — | Disposed | 2890533 | Indirect |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1121190 | Indirect |
| Common Stock | 1864799 | Indirect |
| Common Stock | 43796 | Direct |
Footnotes
F1: E&Healthcare Investment Fund II distributed 1,445,267 shares to its partners on a pro rata basis, for no consideration.
F2: Ms. Kim is the Chief Executive Officer of E&Investment, Inc., which is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and as such, has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein.
F3: Ms. Kim received a pro rata distribution from E&Healthcare Investment Fund II, of which she is a limited partner.